BRAF inhibition in refractory hairy-cell leukemia

New England Journal of Medicine

Volumn 366, Issue 21, 2012, Pages 2038-2040

  Dietrich, Sascha ^a   Glimm, Hanno ^b   Andrulis, Mindaugas ^a   Von Kalle, Christof ^b   Ho, Anthony D ^a   Zenz, Thorsten ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CLADRIBINE; HEMOGLOBIN; PENTOSTATIN; RITUXIMAB; VEMURAFENIB;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG RESPONSE; ENZYME INHIBITION; HAIRY CELL LEUKEMIA; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LETTER; LEUKEMIA REMISSION; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MUTATIONAL ANALYSIS; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE COUNT; TREATMENT DURATION; TUMOR BIOPSY; TUMOR VOLUME;

EID: 84861417677     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1202124     Document Type: Letter

References (5)

1. Grever MR. How I treat hairy cell leukemia. Blood 2010; 115:21-8.
2. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
5. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363: 809-19.